Sponsored by

VGoodiez 420EDC
  • Welcome to VaporAsylum! Please take a moment to read our RULES and introduce yourself here.
  • Need help navigating the forum? Find out how to use our features here.
  • Did you know we have lots of smilies for you to use?

Law The Cannabis Chronicles - Misc Cannabis News

Google Play Store Bans Weed Delivery Apps From Performing Transactions

11049455_419739014878695_2535207781824224427_n-2.png

Weed delivery apps have 30 days to update their interface or be banned from the Google Play store. Facebook/Eaze

Google is cracking down on cannabis distributing apps on its Play app store, whether they’re legal or not.

The tech giant is giving “weed facilitating” app developers 30 days to remove the cart feature from their interface or face being kicked off the Play store.



While the move isn’t meant to ban marijuana content from the platform completely—and follows in the footsteps of Apple’s App Store policy—it does come off as a harsh potential punishment for licensed cannabis dispensaries.

“These apps simply need to move the shopping cart flow outside of the app itself to be compliant with this new policy,” a company spokesperson told The Verge.“We’ve been in contact with many of the developers and are working with them to answer any technical questions and help them implement the changes without customer disruption.”

Some of the popular apps that are expected to feel the effect are Weedmaps and Eaze, which expect to have Android orders slashed once in-app ordering is disabled.

Marijuana legalization advocate Cristina Buccola, a New York-based attorney whose law firm focuses on the cannabis industry, told Observer it’s not shocking to see Google ridding its platform of weed transactions. This is especially true “given the sensitivity around banking when it comes to marijuana,” she explained.

Buccola says the decision is a step backwards for the cannabis industry, in which many small businesses rely on digital apps to educate and market to consumers legally. “It’s a shame because we should be working toward a holistic approach to legalizing cannabis, which includes utilizing online tools like Google’s app store.”

David Holland, the executive and legal director of Empire State NORML (National Organization for the Reform of Marijuana Laws), says Google’s announcement isn’t so much a statement of morality, but a choice not to be the electronic platform by which people can conduct commercial transactions to obtain cannabis, alcohol or tobacco.

“By removing the shopping cart feature, Google is removing some of the responsibility to monitor and ensure the imposition or collection of sales tax,” Holland said. This alleviates the potential burden of verifying that a Google user is in a legalized state and obtaining cannabis legally.

In turn, Buccola see this decision as a rallying cry for passing legislation to help legitimize the industry in these cases. “This is an opportunity for businesses who do want to be bullish about advocating for the e-commerce of legal marijuana,” Buccola concluded.

So there's an opportunity for a more enlightened company to step in where google got too big to take chances.
 
There is a video clip of the entire commity hearing that could not be embedded. To view follow the link in the title. Durbin’s medical cannabis comments start around 1:00:00

Top Democratic Senator Calls Medical Marijuana A ‘Laughing Matter’

Screen-Shot-2019-06-04-at-9.48.17-AM-e1559667044908.png


A top-ranking Democratic senator called into question the therapeutic value of marijuana on Tuesday while also making a broader point about how the federal drug classification system inhibits medical research.

Sen. Dick Durbin (D-IL) made the comments during a Senate Judiciary Committee hearing on the opioid epidemic and federal moves to restrict powerful fentanyl analogues.

Before getting into his views on the potential consequences of permanently placing those opioids in Schedule I of the Controlled Substances Act (CSA), Durbin, the Senate Democratic whip, took a hit at medical cannabis.

“My state just decided in the last few days to make marijuana legal in my state for recreational purposes, starting January 1,” he said, referencing the passage of a cannabis legalization bill through the Illinois legislature last week. “We’ve had medical marijuana. I’ve been to one of those clinics. It was almost a laughing matter.”

“The medical claims they make about marijuana go way beyond anything that’s been proven,” he said. “There are no clinical trials going on.”

Durbin’s views on medical cannabis and marijuana reform in general are at odds with those expressed by many of his Democratic colleagues—not to mention a majority of voters. He said earlier this year that he opposed criminalizing cannabis use, but he cautioned against the other “extreme” of legalizing the plant.

Legalization advocates took issue with Durbin’s characterization of medical cannabis.

“Senator Durbin’s comments surrounding the efficacy and therapeutic benefits of cannabis are ignorant at best and cruel at worst,” Justin Strekal, political director of NORML, told Marijuana Moment. “There are over 30,000 peer-reviewed studies hosted on pubmed.gov on the effects of cannabis, including many showing declines in cases of opioid abuse and overdose fatalities.”

“If Mr. Durbin is serious about addressing the opioid crisis, then he ought not to disparage the role or lives saved that legal marijuana can play,” Stekal said.

Michael Liszewski, principal of The Enact Group, a lobbying and consulting firm that focuses on cannabis, told Marijuana Moment he agrees that the “Schedule I status has prevented more robust medical cannabis research,” but that “it’s disappointing that Senator Durbin is characterizing it as a ‘laughing matter.'”

“To imply that patients need to look sick enough in order to obtain relief from medical cannabis ignores at least two points: First, many ailments that are treated by medical cannabis are not readily visible to observers, such as Crohn’s, lupus, and PTSD (all of which are qualifying conditions in Illinois). And second, it ignores the very real possibility that these individuals look healthy because their medical cannabis therapy is providing them with benefit.”

David Mangone, director of government affairs and counsel at Americans for Safe Access, also criticized the lawmaker’s remarks.

“Senator Durbin’s comments about the medical cannabis program in Illinois are an insult to the thousands of people in his state’s program who use cannabis as a life-saving medicine,” he told Marijuana moment.

“Ignoring the fact that there are nearly 400 [National Institutes of Health] supervised clinical trials on cannabis either underway or recruiting participants, and comparing cannabis to fentanyl analogues, is disingenuous, ill-informed, and dangerous for public policy,” Mangone said.

While the senator was dismissive of medical cannabis at the hearing, arguing that we “are not establishing whether marijuana is in fact medically appropriate in so many circumstances where they claim they are,” he also said that the Schedule I status of cannabis is the reason, in his view, that evidence about its therapeutic benefits of cannabis is insufficient.

“Why don’t they [research cannabis]? Because we’ve moved marijuana to Schedule I—the same place we’re about to move all fentanyl analogues,” he said.

“Under a blanket Schedule I framework, which is being asked for today, we could imperil research into more powerful naloxone—a stronger and better treatment to save lives of those who have used fentanyl analogues,” he added. “Is that what we want to do? I don’t think so.”

Liszewski said there “simply was no need for the senator to slander medical cannabis therapy while making his valid point about how Schedule I status harms medical research.”

Durbin later questioned the Drug Enforcement Administration’s opioid production quota, stating that there’s no need to manufacture such a high volume of prescription painkillers. In one of his closing remarks, he made a play on a Reagan-era anti-drug message.

It’s time to say no,” he said. “Just say no—to pharma when they want that kind of production.”

Though the senator made his thoughts on the scheduling system clear, he’s so far declined to sign on to legislation that would amend the issue, by rescheduling or descheduling cannabis. In fact, Durbin has only cosponsored two marijuana-focused bills over the course of his 36 years in Congress to date.

One would have required the DEA to conduct clinical trials on cannabidiol (CBD) and later determine whether the compound should be a controlled substance. The other would have allowed defendants in federal court cases to introduce evidence showing that any marijuana activity was in compliance with a state medical cannabis law.

Notably, during his time in the House, Durbin cosponsored the Anti-Drug Abuse Act of 1986, which included provisions that expanded the criminalization of drugs as well as a section tied to the problem he complained about at Tuesday’s hearing. That provision amended the CSA “to provide that controlled substance analogues shall be treated as a schedule I substance.”

“I appreciate Senator Durbin’s comments about limiting federal research,” Don Murphy, director of federal policies for the Marijuana Policy Project, told Marijuana Moment. “I’d feel even better about it if he channeled that energy and interest by putting his name on legislation to fix the problem”
 
Statements from the FDA’s first public hearing on CBD

The U.S. Food and Drug Administration held a public hearing on Friday as the agency continues its work to regulate CBD following the legalization of hemp in the 2018 Farm Bill in December. Although the legislation removed hemp and derivatives containing less than 0.3 percent THC, the 2018 Farm Bill also granted the FDA the authority to regulate cannabis compounds including CBD. The agency then announced that CBD could not be used as a dietary supplement or ingredient in foods until regulations have been drafted. Friday’s hearing was the first opportunity for members of the public to provide input to the agency on the subject.

In a Federal Register notice requesting comments from the public at the hearing, the FDA noted that more research is needed on CBD.

“Questions remain regarding the safety considerations raised by the widespread use of these products,” the notice reads. “These questions could impact the approaches we consider taking in regulating the development and marketing of products.”

Potential Risks of CBD
The FDA has approved one prescription CBD medication, Epidiolex, for the treatment of severe epilepsy. In clinical trials for the drug, high doses of CBD were generally well tolerated by patients but some did experience side effects including lethargy and gastrointestinal distress. The FDA is also concerned about potential liver problems from high doses of CBD.

“This is a potentially serious risk that can be managed when the product is taken under medical supervision in accordance with the FDA approved labeling for the product,” FDA officials wrote in the Federal Register notice. “But it is less clear how this risk might be managed if this substance is used far more widely, without medical supervision.”

Dietary Supplement, Medicine, or Both?
More than 400 applicants had requested to testify at the hearing, leading the FDA to resort to a lottery system to select 120 speakers who were each allowed either two or five minutes to address the panel. One of them, Dr. Stuart Titus, the CEO of Medical Marijuana Inc., a manufacturer of a wide range of hemp-based CBD products, told High Times in a telephone interview that he believes regulators should establish a dual system of CBD regulation.

“Our goal was to try to carve out a nice pathway for the FDA to regulate CBD as both a medicine and a dietary supplement,” Titus said.

He added that regulating highly refined CBD formulations as medicines and allowing CBD in its natural botanical form as a dietary supplement or food ingredient would comply with existing regulations while preserving the will of Congress in legalizing hemp.

“We are certainly quite excited about the application for individuals to be able to use CBD without necessarily being sick or having to go to the doctor to get a prescription,” said Titus.

In his testimony at Friday’s hearing, he said that consumers should be allowed to include CBD as part of their diet.

“We believe that non-psychoactive hemp products containing CBD and other cannabinoids, as they support our endogenous cannabinoid system, are an essential nutritional supplement for optimal health, just as is Vitamin C,” Titus told the FDA panel. “In addition, botanical hemp products containing CBD are safe and extremely well-tolerated.”

But not all of those testifying at the FDA hearing agreed with the assessment that CBD and other hemp compounds are safe. David Evans, a lawyer for Cannabis Industry Victims Educating Litigators, told the panel that he has 1,000 opioid cases pending against the pharmaceutical industry.

“If our dreams come true, we’ll have the same thing going against the marijuana industry in a year or two,” said Evans.

The FDA has not announced a timeline for creating the regulations for CBD but media reports estimate that it will take months, if not years. Some hemp industry leaders and former FDA Commissioner Scott Gottlieb have suggested that a legislative solution from Congress may be necessary.
 
This statement I will make really isn't partisan...its just my personal observation that this lady will seemingly say just about anything and adopt just about any position in order to try to break the 1% or less support she has in Dem primary polls.

Not just MJ but she has flipped on a wide range of issues in her pursuit of higher office.

Don't believe me? Just search for it yourself....you will find it.


Presidential Candidate Gillibrand Unveils Wide-Ranging Marijuana Legalization Plan


Sen. Kirsten Gillibrand (D-NY) unveiled a comprehensive marijuana reform plan on Wednesday that involves legalizing the drug nationwide, expunging non-violent convictions and requiring that private and federal health insurers to cover medical cannabis.

The 2020 Democratic presidential candidate also said she would immediately deschedule marijuana, allow cannabis businesses to access financial services and impose an excise tax on legal sales that would fund programs designed to help communities that have been disproportionately impacted by prohibition.

In a Medium post, the senator walked through the details of her proposal, emphasizing the importance of social equity and creating a regulatory system that protects patients, boosts the economy and normalizes the industry. She said ending federal marijuana prohibition “will be a top priority of my presidency.”

“As president, I will immediately deschedule marijuana as a controlled substance, and start working to not only heal the damage done by racist drug laws, but tap into the medical and economic opportunity that legal marijuana offers,” Gillibrand wrote.

One of the more novel elements of her proposal concerns health coverage for medical cannabis. Gillibrand has repeatedly stated that marijuana can serve as an alternative to addictive opioid painkillers, and she said mandating coverage for all private insurers as well as the federal programs Medicare and Medicaid will help suffering patients.

Another prominent feature of the plan centers on social equity for communities ravaged by the war on drugs. Besides providing for the expungement of non-violent marijuana convictions, Gillibrand is also proposing using tax revenue from cannabis sales to fund programs such as job training and education for disadvantaged communities.

She also wants to give small businesses—particularly those owned by women and minorities—access to capital and “technical assistance” so that they can more easily participate in the legal industry.

Gillibrand’s plan earned early praise from Wanda James, the first black woman to own a dispensary in Colorado who penned an editorial in Blavity on Wednesday.

James said that the senator’s plan “goes far and beyond any proposal I’ve seen from a presidential candidate” and that her “agenda was built with economic equity in mind.”

“[L]et’s get really real: Kirsten Gillibrand is a white woman who hasn’t experienced the same type of discrimination as my brother or me,” James wrote. “But she’s doing everything she can to understand and to try to make up for the generations of injustice — and she’s a fighter who’s brave enough to lead on the issues where others won’t.”

Gillibrand made a similar point in her Medium post.

“Nothing proposed today can ever undo the devastating harm done to generations of communities and families of color by the War on Drugs,” she wrote. “But it’s long past time to start making this right. With this plan, we can begin to dismantle the institutional racism in our criminal justice system, open up important new medical and economic horizons, and lift up communities who need and deserve a fair shot at opportunity.”

Gillibrand said that the country should end prohibition for some of the same reasons that it ended alcohol prohibition:

“Fundamentally, whether adults use marijuana is a matter of privacy, and we should treat marijuana as a major economic opportunity and revenue source.”

1_I7ZyCkp9ag20MhXfR4ePHg-1024x1024.png

Via Team Gillibrand.

She further argued that while state-level legalization efforts have had “positive benefits,” establishing a federal regulatory framework is necessary because “a state-by-state patchwork is not enough to tackle the deeply rooted racial, social, and economic injustices within our marijuana laws, or to fully unleash the economic equity and opportunity of marijuana legalization.”

It’s not clear whether Gillibrand plans to introduce legislation containing any of these proposals during the current Congress or if she’s just outlining her cannabis agenda if elected president. The plan’s reveal comes weeks after the senator met with advocates and discussed how marijuana reform fits within her campaign.

What is clear is that the wide-ranging proposal is yet another sign that Democratic presidential candidates are taking the issue of marijuana reform seriously. For many voters, it’s no longer enough for politicians to simply voice support for reform; candidates are now essentially competing to produce the most forward-thinking cannabis plans to stand out in an overwhelmingly pro-legalization crowd.

“It’s 2019. It’s time to legalize marijuana nationwide,” Gillibrand wrote. “As president, I’ll get it done.”
 
GOP Senator Sheds Light On Behind-The-Scenes Marijuana Reform Discussions

Screen-Shot-2019-06-06-at-8.56.31-AM-e1559836793998.png


Sen. Cory Gardner (R-CO) said on Wednesday that he has “pretty good confidence” that Congress will pass far-reaching marijuana reforms this year, citing conversations he’s had with key committee chairs and President Donald Trump.

Gardner, who is the lead GOP sponsor of separate bills to let cannabis businesses access banking services and to protect states that have legalized from federal interference, said bipartisan support for his legislation “sends a strong signal that it’s time to pull the federal government’s head out of the sand on marijuana and actually address” the issue.

“It’s a sign that it’s no longer acceptable for the status quo [to continue] and we need to actually fix this conflict in federal and state law,” he said.

The senator revealed that he’s had “a number of good conversations” with Sen. Lindsey Graham (R-SC), who chairs the Senate Judiciary Committee, as well as “some of the others in key committees like the Banking Committee.”

“I actually have some pretty good confidence that we can move forward on a solution this year,” Gardner told Yahoo Finance. “I think the consistent drumbeat of businesses and organizations and individuals going in to share their story with Chairman Graham and others has really made a key difference in terms of how we’re going to pass legislation to actually fix this conflict.”

Of course, cannabis reform legislation would also have to be signed by Trump, who Gardner said he considers an ally on the issue.

“I think the president would look at it as a commonsense approach that helps him out as well,” he said in response to a question about whether passing the bill he is co-leading with Sen. Elizabeth Warren (D-MA) could aid her presidential campaign as she seeks to oust the incumbent occupant of the Oval Office. “He’s been supportive of this approach from the get-go. The conversations I have had with him over the past year-plus have been very productive.”

“I think that this is something he understands needs to be done because of the number of states—47 states have now moved forward—and to use his term, we’re not going to go backwards on this. Let’s fix the problem,” he added.

While Trump has not been particularly vocal about the issue since being elected, he did say last year that he “really” supports legislation to let states set their own marijuana policies without federal intervention when asked by a reporter.

Meanwhile, a number of political observers have pointed out that bringing home a federal cannabis win of some kind or another to Colorado could go a long way toward aiding Gardner’s own bid to be reelected next year.
 
"Federal Reserve said on Wednesday that the department would clarify to banks that hemp is a legal crop"

Somebody needs to tell those assholes in Idaho who are prosecuting the fucking truck drivers of an industrial hemp load....sigh.



Federal Reserve Official Pledges To Tell Banks They Can Service Hemp Businesses

A top official with the Federal Reserve said on Wednesday that the department would clarify to banks that hemp is a legal crop and that they are allowed to provide hemp businesses with financial services without violating the law.

During her confirmation hearing for a renewed term, one of the Fed’s board members was pressed on what kind of guidance the department was providing to banks since the 2018 Farm Bill federally legalized hemp and its derivatives. Michelle Bowman said they generally refer the financial institutions to existing anti-money laundering legislation.

Sen. Jon Tester (D-MT) said that hemp farmers in his state “still face barriers to access to the financial system” and that additional clarification is warranted.

“Senator, this is an important issue that when I meet with bankers from across the country, many states have engaged heavily in this crop for growth,” Bowman said at the Senate Banking, Housing and Urban Affairs Committee hearing, where she must be confirmed after being renominated for her position.

Watch the conversation about hemp and banks starting at about 1:07:15 into the video below:

While the Fed emphasizes the importance of assessing which clients banks take on, “we absolutely tell them that it’s not our job or our role to tell them who their customers should be and that they should understand what their business strategies and risks are with respect to any customer that they have,” she said.

The senator asked specifically how the department is advising this institutions when it comes to hemp, and Bowman said “we have not told them that they cannot bank them.”

Tester argued that while he and the Fed official might be on the same page, it’s possible that banks were hearing a different message—hence why hemp businesses have said that they’re still experiencing difficulties accessing credit. He said clarification is especially important at this stage because of fallout from trade wars with China and Mexico, as hemp represents a potentially lucrative crop for American farmers.

“I would agree with you. We would not discourage banks from banking these types of customers,” Bowman said. “We’ll try to clarify that. Hemp is not an illegal crop.”

“That’s what I wanted to hear,” Tester said.

Last month, Rep. Andy Barr (R-KY) similarly implored federal financial regulators to update their guidelines so that hemp and CBD businesses know that they have access to their services just like any other legal commodity.

Senate Majority Leader Mitch McConnell (R-KY), who led the charge to legalize hemp, also offered to introduce standalone legislation to resolve any “glitches” in the implementation of his provision. He successfully inserted language into a disaster bill last month that ensures hemp farmers have access to federal crop insurance.
 

@momofthegoons @Shredder

As I commented on under another thread:

This is such complete and utter BS and this Coroner really needs to review the basis of scientific knowledge and proof. Coming from a legal medical professional, this conclusion is both atrocious and imbecilic.

What they KNOW is this: they don't know what killed her

They PRESUME this: that it was MJ that killed her because she had THC in her blood at the time of death.

See the gap here? sigh
 
Gardner should be asked to support the Schumer-Jerries de-scheduling bill

GOP Senator Sheds Light On Behind-The-Scenes Marijuana Reform Discussions

Screen-Shot-2019-06-06-at-8.56.31-AM-e1559836793998.png


Sen. Cory Gardner (R-CO) said on Wednesday that he has “pretty good confidence” that Congress will pass far-reaching marijuana reforms this year, citing conversations he’s had with key committee chairs and President Donald Trump.

Gardner, who is the lead GOP sponsor of separate bills to let cannabis businesses access banking services and to protect states that have legalized from federal interference, said bipartisan support for his legislation “sends a strong signal that it’s time to pull the federal government’s head out of the sand on marijuana and actually address” the issue.

“It’s a sign that it’s no longer acceptable for the status quo [to continue] and we need to actually fix this conflict in federal and state law,” he said.

The senator revealed that he’s had “a number of good conversations” with Sen. Lindsey Graham (R-SC), who chairs the Senate Judiciary Committee, as well as “some of the others in key committees like the Banking Committee.”

“I actually have some pretty good confidence that we can move forward on a solution this year,” Gardner told Yahoo Finance. “I think the consistent drumbeat of businesses and organizations and individuals going in to share their story with Chairman Graham and others has really made a key difference in terms of how we’re going to pass legislation to actually fix this conflict.”

Of course, cannabis reform legislation would also have to be signed by Trump, who Gardner said he considers an ally on the issue.

“I think the president would look at it as a commonsense approach that helps him out as well,” he said in response to a question about whether passing the bill he is co-leading with Sen. Elizabeth Warren (D-MA) could aid her presidential campaign as she seeks to oust the incumbent occupant of the Oval Office. “He’s been supportive of this approach from the get-go. The conversations I have had with him over the past year-plus have been very productive.”

“I think that this is something he understands needs to be done because of the number of states—47 states have now moved forward—and to use his term, we’re not going to go backwards on this. Let’s fix the problem,” he added.

While Trump has not been particularly vocal about the issue since being elected, he did say last year that he “really” supports legislation to let states set their own marijuana policies without federal intervention when asked by a reporter.

Meanwhile, a number of political observers have pointed out that bringing home a federal cannabis win of some kind or another to Colorado could go a long way toward aiding Gardner’s own bid to be reelected next year.
 
i got to try deep fried pizza once.

Everything tastes better fried! hahaha Well, until it kills you! LOL

You can batter dip and deep fry shoe leather and I would eat it! haha
 
90


Roberto Gonzalez, the general manager of Western Oregon Dispensary in Sherwood, Ore., waits for customers. The dispensary is one of two medical-only marijuana dispensaries left in Oregon. | Gillian Flaccus/AP Photo

State efforts to grow pot industries clash with federal law
Insurers won’t cover drug the feds still ban.

This story was published as part of a POLITICO Journalism Institute special section. PJI is a journalism training program in partnership with American University and the Maynard Institute, that allows student participants to report and produce news stories.

State legislatures across the country are taking steps to protect medical marijuana users, but many patients face hurdles when accessing the drug because insurance companies won’t cover a substance that remains illegal under federal law.


Illinois is poised to become the latest state to legalize adult recreational use of marijuana, and the bill approved by the state Legislature on May 31 would allow medical users to grow marijuana at home and require cannabis businesses to keep reserves for patients in case of shortages.

New Jersey’s Department of Health announced Monday that it will significantly boost the number of licenses it distributes in hopes of expanding the state’s medical marijuana program.

But accessing medical marijuana remains difficult for some patients, even in states that hope to permit its use, cannabis advocates say. Because cannabis remains classified as a Schedule 1 drug under the Controlled Substances Act, the Food and Drug Administration has not approved it to reduce pain, treat anxiety or provide other much-touted health benefits.

Typically, insurance companies cover the costs of only FDA-approved drugs, so patients cannot use their health insurance policies for their prescription or application fee, said Shanita Penny, president of the Minority Cannabis Business Association, a lobbying group. Those patients have to pay out-of-pocket costs that Penny said can add up to more than $900 in some states after patients pay the application fee, buy required paraphernalia and obtain the drug.

Virtually every Democrat seeking the party’s 2020 presidential nomination has called for legalizing adult recreational use. Sen. Kirsten Gillibrand (D-N.Y.) on Wednesday unveiled a plan that would include requiring health insurers, including Medicaid and Medicare, to cover medical marijuana.

“We’ve made great progress in recent years on legalizing marijuana at the state and municipal level, and we’ve seen the positive benefits in states like Colorado, Washington, and more,” Gillibrand said in a statement. “But a state-by-state patchwork is not enough to tackle the deeply rooted racial, social, and economic injustices within our marijuana laws, or to fully unleash the economic equity and opportunity of marijuana legalization.”

Under the current system, the high cost of regulated medical marijuana puts it out of reach for many patients who would otherwise be eligible to use it. They include many people of color, who have also been disproportionately affected by marijuana law enforcement, according to several studies. The Drug Policy Alliance found in 2018 that while arrest rates for marijuana possession have decreased as more states legalize the drug, Latinx and black people are still more likely to be arrested despite similar usage rates among white people.

Penny said some dispensaries work to have discounts for veterans or patients, like gifting $50 worth of medicine if the application fee is $50, but the recurring cost of the drug is too expensive for some.

Penny said that burden is leading some patients who could obtain marijuana from state-approved businesses to buy it more cheaply from dealers who operate illegally.

“They’re not seeking it from a dispensary because the price point is too high,” Penny said. “You do see, especially people from minority communities, folks that are low income, continuing to purchase this medicine from the unregulated market. Because it is at least accessible to them still.”

Including Illinois, 10 states and the District of Columbia have legalized recreational marijuana use by adults, and 33 states have approved its use for medical purposes, which Penny said can include preventing nausea, such as among chemotherapy patients, and treating epilepsy. But federal rules have hindered the industry’s growth by making banks wary of working with pot businesses and blocking research into the drug’s effects.

Some lawmakers are trying to fix that gap between state and federal law, with little success so far. One proposed solution is a bill introduced by lawmakers from states with legal marijuana markets, including Colorado and Massachusetts. The STATES Act would exempt individuals and corporations who comply with state marijuana laws from federal law enforcement.

Critics, however, say that approach would just add complexity since it does not address the Schedule 1 classification. And opponents of legalization, including many congressional Republicans, say marijuana is a dangerous substance that should not be accessible. Colton Grace of the anti-pot legalization lobbying group Smart Approaches to Marijuana said states that are allowing marijuana use do so for commercial reasons.

“The industry is not interested in public health and safety, they’re interested in profit,” Grace said. “Because of that, they’re doing anything they can to roll back regulations and increase that profit.”

But states that have legalized marijuana have more regulation, making the product safer, according to Penny.

Mischa Sogut, legislative director of New York’s State Assembly Health Committee, said the state’s health department is working to create a more accessible medical marijuana program. According to the department's website, it waives the $50 application fee required by the state’s 2014 Compassionate Care Act for all patients and their caregivers.

Still, Sogut said prices at dispensaries in New York can vary and some dosages are priced high in an effort to make a profit. The lack of insurance coverage for marijuana hurts businesses’ ability to expand, Sogut said.

It’s hard “to lower prices too much as long as they’re not profitable, but if they don’t lower prices, since it’s not covered by insurance, it limits their ability for patients to pay, and then they can’t bring in more patients,” Sogut said. “They’re in a bit of a circle with this.”

Furthermore, federal Medicaid plans do not cover the cost of the drug, even if a physician recommended it. State Medicaid programs in legal states may offer coverage if no federal funding match is requested, Sogut said, adding that New York could create a pilot program for marijuana similar to its coverage for abortions and services for undocumented immigrants.

However, he said a federal solution is needed for commercial insurance companies, which comply with federal law even though they’re permitted to cover cannabis under New York law.

“There are things you can do, but I don’t think you’re going to get to widespread, universal commercial insurance coverage until there’s a federal change,” Sogut said. “If there’s a federal change, that’s when you’ll start to see [marijuana] on drug formularies like a normal health care prescription drug.”

Justin Strekal, political director for the National Organization for the Reform of Marijuana Laws, said states could also drive down costs for patients by relaxing limitations on dispensaries and growers and approving more permits.

“When you have a very limited number of businesses competing for consumers, due to arbitrarily decided licensing accounts, it runs contrary to American principle of a free marketplace,” Strekal said. “There’s no logical justification other than pure greed to restrict the number of licenses being issued.”

Illinois state Sen. Heather Steans, a co-author of the recently passed bill, said that her state’s medical program is well-regulated. She said the legislation would lead to new tax revenue that will be used to reinvest in communities that have disproportionately been targeted by drug enforcement.

Still, she said federal law needs to change to make medical marijuana more accessible.

“As states continue to make changes on cannabis laws, I think the federal government needs to act. Federal lawmakers really do need to act,” Steans said.
 
Federal Government Violated The Law In Marijuana Scheduling Evaluation, Group Says

The federal government erred in its scientific evaluation of marijuana’s therapeutic value and must take steps to correct the issue, a libertarian think tank said in a formal filing on Wednesday.

The Competitive Enterprise Institute (CEI) submitted the request for correction to the U.S. Department of Health and Human Services (HHS), which sent the Drug Enforcement Administration (DEA) a letter about the medical value of cannabis in 2015 that served as the basis for its ongoing status as a Schedule I drug.

But that letter lacked an important element required under the federal Information Quality Act. As a “highly influential scientific assessment” that played a central role in the DEA’s decision to maintain marijuana’s strict prohibition, HHS was required to conduct a scientific peer review of evidence on cannabis and its therapeutic potential.

No such peer review occurred, and CEI argued that HHS should therefore “formally withdraw its evaluation” and “inform the public that the information disseminated should not be relied upon for regulatory or other purposes until a proper peer review has been completed.”

CEI also asked the agency to let the DEA know that HHS “did not follow the proper procedures for being relied upon in such a regulatory proceeding.”

The DEA took great stock in the HHS evaluation in question. In its 2016 denial of a petition to consider rescheduling marijuana, it heavily cited the agency’s findings, which “concluded that marijuana has a high potential for abuse, has no accepted medical use in the United States, and lacks an acceptable level of safety for use even under medical supervision.”

But as CEI pointed out, multiple medical associations and a majority of the public have reached a starkly different conclusion. And because HHS failed to conduct a peer review of the subject, that represented a violation of several provisions outlined in an Office of Management and Budget (OMB) memo on ensuring the quality of scientific information that’s disseminated by the agency.

“Because no peer review was done, the requirements of OMB concerning selection of reviewers, independence, choice of peer review mechanism, opportunity for public participation in the peer review process, and certification of compliance were all violated by HHS,” CEI wrote.

HHS now has 120 days to respond to the group’s request for correction.

“Given that 33 states have legalized medical marijuana, it’s clear that federal policy could be significantly changed by a reassessment of this subject,” Devin Watkins, a CEI attorney, said in a press release.

“The peer review required by the Information Quality Act could play a major role in a reassessment of medical marijuana and would ensure that agencies cannot use uninformed opinion to claim a scientific basis for public policies,” he said. “Independent experts should evaluate the opinion of the agency and inform the agency when it is mistaken.”

Actual letter found here:
https://www.scribd.com/embeds/41316...ons=false&access_key=key-39qBYskUWkkv4RmAP3tt
 

Anti-Marijuana Lawmakers Shut Down By Congressional Committee

Marijuana reform advocates scored two victories on Tuesday after a key congressional committee approved a spending bill that included a cannabis banking provision and excluded another rider that previously impeded legalization in the nation’s capital. The moves came in spite of impassioned objections from a handful of Republican lawmakers.

For the first time ever, the House Appropriations Committee passed spending legislation that would provide protections for banks that service marijuana businesses. And a longstanding provision prohibiting Washington, D.C. from using its own local tax dollars to implement a legal cannabis sales system was not included in the bill.

The banking provision states that no funds distributed through the legislation “may be used to penalize a financial institution solely because the institution provides financial services to an entity that is a manufacturer, a producer, or a person that participates in any business or organized activity that involves handling marijuana, marijuana products, or marijuana proceeds” in a jurisdiction where it’s legal.

Rep. Chris Stewart (R-UT) introduced an amendment at the meeting that would have limited the banking protection to the medical cannabis market only, but following extensive pushback from a bipartisan coalition of members, he ultimately withdrew the amendment before forcing a losing vote.

The congressman said that he supports medical cannabis, which voters in his state legalized last year, but felt providing a safeguard for businesses operating in compliance with broader state recreational marijuana laws sends the wrong message from the federal government. He went so far as to say that he didn’t mind if these businesses and their employees are at risk of robberies because they’re operating on a largely cash basis.

“I guess I’m just willing to say a company that’s selling recreational marijuana to our youth and to others, I don’t really care if they have a threat of cash sitting in their basement, if they’re paying their employees in cash,” Stewart said. “I don’t want to make life easier for them. I want to make it more difficult.”

Reps. Mike Quigley (D-IL), Tom Graves (R-GA), Betty McCollum (D-MN), Barbara Lee (D-CA), Brenda Lawrence (D-MI) and David Joyce (R-OH) all voiced opposition to the amendment.

Graves and McCollum argued that excluding the adult-use market from the banking provision would create even more confusion and uncertainty in the financial sector. How would banks be able to differentiate revenue derived from medical versus recreational cannabis sales at shops that sell both, they asked, for example.

“This really isn’t about the issue of medical marijuana and recreational marijuana. The issue is more about states’ rights, quite frankly,” Graves said. “It’s really, really important in my viewpoint that we eliminate some gray space—that we make sure that the rules are defined.”

“It becomes very complicated very fast,” McCollum said of the proposed amendment. “What we want to have is transparency, accountability and confidence in our tax system and our banking system.”

Reps. Harold Rogers (R-KY) and Andy Harris (R-MD) said they supported the amendment, with both focusing on marijuana’s legal status under federal law and warning that approving the provision would encourage more usage.

“Bottom line is what we’re going to do here today is send a message: Is recreational marijuana a thing that the federal government should be promoting?” Harris said.

“There is no state where it’s legal under federal law. It is a gateway drug,” he said. “This is a huge money-making industry. This is Big Cannabis.”

While more financial institutions have been willing to accept cannabis business accounts, many banks still fear being penalized by federal regulators given the lack of clarity on the issue. In 2014, a similar amendment addressing the issue was approved in a House floor vote but it was never enacted into law. The Appropriations Committee rejected a marijuana banking amendment after it was introduced before the panel last year.

Bipartisan legislation that cleared the House Financial Services Committee in March would resolve the problem, but that bill represents a permanent fix whereas this appropriations provision must be annually renewed.

The standalone Secure And Fair Enforcement (SAFE) Banking Act is expected to go before the full House in coming weeks. It currently has 206 cosponsors—nearly half of the chamber.

“Today’s small victories demonstrate an appetite for greater protections of the reform movements progress,” Justin Strekal, political director of NORML, told Marijuana Moment. “Our staying power is undeniable in the effort to end federal prohibition and criminalization.”

Reform advocates secured another victory with the bill’s passage: A provision that has blocked the District of Columbia from spending local taxpayer dollars to legalize and regulate cannabis was excluded from the legislation.

Earlier years’ versions of the bill stipulated that D.C. couldn’t use appropriated funds “to enact any law, rule, or regulation to legalize or otherwise reduce penalties associated with the possession, use, or distribution of any schedule I substance under the Controlled Substances Act or any tetrahydrocannabinols derivative for recreational purposes.”

Voters in Washington, D.C. legalized marijuana possession and cultivation in 2014, but the congressional provision left lawmakers with their hands tied when it came to regulating the plant.

Harris, who first introduced the provision, was expected to introduce an amendment get his language back into the spending legislation during Tuesday’s committee markup, but instead focused on introducing amendments to block the decriminalization of sex work in D.C. and creating regulatory exceptions for private schools in the District, while declining to mention the cannabis provision. The panel rejected both of his D.C. proposals.

“The man who has unapologetically been offering up this rider and fighting for it for years didn’t even bother to introduce the amendment,” said Queen Adesuyi, policy coordinator with the Drug Policy Alliance. “He knew it was going to lose and lose badly. His waving white flag gives us optimism on our ability to secure this win and free D.C. to implement legalization through a racial justice lens the way D.C. residents intended.”

Don Murphy, director of federal policies for the Marijuana Policy Project, told Marijuana Moment that the cannabis rider’s removal from the bill is “a win for the voters of the District, and although it may be low hanging fruit, it sure tastes sweet.”

The appropriations process—which has historically been the only vehicle through which Congress has enacted marijuana policy changes—is being leveraged to address a wide range of cannabis reform proposals this session.

Reports that have been released by the Appropriations Committee this year include calls for medical cannabis research expansion, implementing hemp regulations, establishing regulations for CBD, preventing impaired driving and protecting benefits for military benefits.

On Monday, the panel also published a report urging the federal government to reconsider its employment policies as it concerns federal workers who use cannabis in compliance with state law.

The same day, the House Rules Committee, another powerful panel, cleared an amendment for floor consideration that was introduced by Rep. Alexandria Ocasio-Cortez (D-NY), eliminating a rider prohibiting the use of federal funds for “any activity that promotes the legalization of any drug or other substance in Schedule I.”

The purpose of the legislation is to remove barriers to research into the potential therapeutic use of such substances, including cannabis, psilocybin and MDMA, the congresswoman said.

But the panel declined to advance a separate amendment from Rep. Lou Correa (D-CA) that would have barred the Department of Education from denying or limiting “any funding or assistance to institutions of higher education” where the use or possession of cannabis is permitted.

The committee chairman, Rep. Jim McGovern (D-MA), told Marijuana Moment the amendment wasn’t made in order for procedural reasons and that he will “continue to welcome and encourage debate on marijuana policy.”

The spending bill covering the Treasury Department and funding for Washington, D.C. that was approved the the appropriations panel next heads to the Rules Committee, which will decide which further amendments, potentially including cannabis-related ones, can be considered on the floor.
 
Americans want legal weed for these reasons


We are not sure when it happened, but somewhere along the 20-some years of statewide marijuana legalization in the United States, the goal of the smoke for the average user has shifted. While cannabis legalization started with a serious tone surrounding its medicinal effects it also was once a deal where recreational cannabis use was a kind of comic relief, a way to put the absurdity of the day in the rearview and just laugh it up and appreciate the good times to be had.

Today, in light of recreational legalization, there are advocacy groups still out there on a mission to get the government or whoever will listen to understand that the therapeutic benefits of this plant are vast and should be respected as a legitimate medicine and this message seems to be working. Over half the nation has now legalized the leaf for medicinal use in some form or fashion. It’s a trend that has apparently given people all across the country a new reason to join the American cannabis clique.

Some of the latest data from the American research firm Nielson shows that 34% of adults 21 and over are now intrigued about using marijuana. But rather than explore the head change that the herb is famous for providing, many of these people are more interested in checking out the weed scene as a way to improve their overall health. The new survey shows that the majority of the country’s cannabis curious are eager to try pot as a combative measure against a variety of physical and mental conditions ranging from chronic pain to a relaxation aid.

The new survey shows that the majority of the country’s cannabis curious are eager to try pot as a combative measure against a variety of physical and mental conditions.

Statistics show that the biggest reason Americans want legal weed is to control pain (85%). This response is likely the result of several studies published over the past few years showing that pot could be an effective alternative to some prescription painkillers. It is just one of the reasons that cannabis components like hemp-derived CBD, which has been shown to have anti-inflammatory properties, has become such a huge household name as of late.

The next reason America gave for wanting legal weed is improving their overall mental health (82%). It seems that more people are starting to realize that the tragedies of life are a little less soul-slashing with a head full of THC.

And they’re not wrong.

Some folks would like to try marijuana as a remedy for minor injuries (81%), and others simply want it to relax (74%). There are those, as well, who want it for a non-pain-related medical issue (63%), preventative medicine (60%), and two or three hippies said they would like it to enhance their spirituality. In the end, all everyone wants is the freedom to be high.

Although the mainstream media might size up all of this chatter to a society that has progressed from burn-outs and stoners to the wellness-minded, we’ve got to tell you, it is a fine line. All of the reasons America has given for wanting legal marijuana are just an elaborate dissection of what it actually means to be high. The improved mental state and the relaxation is precisely why people have been using marijuana for thousands of years. We hate to break it to you America, but being stoned is the same as being medicated.

The Nielsen survey shows that nearly 50% of the respondents said they would consume marijuana as a way to have fun with friends. Translated, this means that half of the nation wants to get high with their buddies and relish in life, love and laughter. This is what is often referred to as recreational use. So far, 11 states have legalized cannabis for this purpose, and it is the direction the United States is going with respect to changing the cannabis laws nationwide.

You may have heard this concept articulated as “sold in a manner similar to alcohol,” which is how legalization was pitched years ago during the campaign phase of the initiatives to establish taxed and regulated pot markets in Colorado and Washington. Now, most of the nation dig this idea. Some of the latest public opinion polls indicate that more than 60% of the population would like to see cannabis legalized like alcohol and tobacco.

So, what did we really learn from the study? Well, while it might show that America is mostly interested in weed for its medicinal benefits, the cipher buried deep within the edges of the verbiage really just drives it home how much people want marijuana as a muse to all highness. And to that we say, cool!
 
I like that last article, maybe because I agree with it: to me, “normal” use IS medicinal *AND* I get high. The two are not separable for me. Cannabis for me has always been pro-life in a profound and deeply personal way.

What I see happening is that fewer and fewer people are afraid of being high.
 

Sponsored by

VGoodiez 420EDC
Back
Top